RT 5mg

Guangzhou Boyuan Outdoor Products Co., Ltd. is a modern enterprise located in Guangzhou, China, specializing in the research, development, and supply of high-purity peptide raw materials. Although the company name includes the word "Outdoor Products," Boyuan's core business is deeply rooted in the fields of biochemistry and laboratory research, and the company is dedicated to providing high-quality peptide products to research institutions, laboratories, and professional buyers worldwide. With years of industry experience, a strict quality control system, and an efficient global logistics network, Boyuan has rapidly developed into a trusted partner in the peptide raw material supply chain. The company's main products cover dozens of popular research peptides, including Semaglutide, Tirzepatide, Retatrutide, HCG, TB-500, GHK-CU, and many others, with specifications ranging from milligram to gram levels to meet the procurement needs of different scales. Boyuan always adheres to the business philosophy of "Quality First, Customer Supreme," and each batch of products is tested by High-Performance Liquid Chromatography (HPLC) to ensure purity of over 99%, with third-party test reports available upon customer request. In terms of warehousing and logistics, Boyuan has multiple warehouses within China and overseas, enabling rapid sorting and global shipping while supporting cold chain transport to ensure the stability of peptide products during transit. Whether for small batch purchases or bulk orders, Boyuan offers flexible and efficient solutions. Furthermore, Boyuan has a professional technical support and customer service team, providing product consultation, usage guidance, and after-sales follow-up, truly delivering a worry-free experience from order placement to receipt. Boyuan accepts various payment methods, including bank wire transfers, PayPal, credit cards, and cryptocurrencies in some regions, greatly facilitating transaction needs for customers from different countries. Based on market feedback, Boyuan's products have received high praise from customers, who generally agree that the products have stable purity, rapid reconstitution, good batch-to-batch consistency, and clear advantages in price compared to similar suppliers. Many customers specifically mention Boyuan's professionalism in packaging and logistics, noting that the cold chain packaging is robust with sufficient ice packs, ensuring the product remains in good lyophilized condition even after long-distance transportation. The company has established long-term and stable cooperative relationships with research institutions and distributors from countries such as the United States, Germany, the United Kingdom, Australia, Brazil, and South Korea. Boyuan will continue to develop in the peptide field, enriching its product line, improving quality control standards, optimizing its global logistics network, and actively exploring cooperation opportunities with research institutions. The company plans to introduce more novel peptide products in the future, including but not limited to research molecules such as MOTS-c, SS-31, and FOXO4, while further improving the product traceability system and customer service system. Boyuan believes that through continuous effort and innovation, it can provide global researchers with a better, more convenient, and more reliable experience in sourcing peptide raw materials.

Among Boyuan's extensive product portfolio, Retatrutide represents one of the most innovative and scientifically advanced peptides available today. Retatrutide, also known by its research code LY3437943, is a first-in-class triple hormone receptor agonist that simultaneously targets three key metabolic pathways: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. This triple agonism mechanism sets Retatrutide apart from all other incretin-based peptides currently on the market, including dual agonists like Tirzepatide and single agonists like Semaglutide. Developed originally by Eli Lilly and Company, Retatrutide has generated substantial excitement within the global scientific community due to its potential to address multiple aspects of metabolic disease simultaneously. In Boyuan's product catalog, Retatrutide is presented under the RT series, with available specifications including RT5, RT10, RT15, RT20, RT30, RT40, and RT60. Each catalog number represents the milligram strength per vial, and each box contains ten vials. The product is supplied as a white to off-white lyophilized powder in borosilicate glass vials with butyl rubber stoppers and flip-off aluminum seals. The CAS number of Retatrutide is 2381089-83-2, its molecular formula is approximately C₂₂₁H₃₄₂N₄₆O₆₅, and its molecular weight is approximately 4735 Daltons. Boyuan ensures that each batch of Retatrutide meets a purity of at least 99% by HPLC, with water content below 5%, acetate content below 12%, and bacterial endotoxins below 1.0 EU per milligram. The unopened lyophilized powder should be stored at -20°C in a dry, light-protected environment, where it remains stable for up to 24 months. Retatrutide is intended for laboratory research use only and is not for human diagnostic, therapeutic, or clinical applications.

Retatrutide is a synthetic peptide consisting of 39 amino acids, and its chemical structure incorporates several key modifications that differentiate it from native GIP, GLP-1, and glucagon. One of the most important modifications is the attachment of a fatty diacid moiety to the side chain of a lysine residue, which promotes strong binding to serum albumin and significantly extends the plasma half-life of Retatrutide to approximately six days. This extended half-life supports once-weekly dosing in research settings and makes Retatrutide an excellent tool for long-term in vitro and in vivo studies requiring sustained receptor activation. Additionally, the amino acid sequence of Retatrutide incorporates specific substitutions that enhance its stability against enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). Unlike native GIP and GLP-1, which are rapidly degraded by DPP-4, Retatrutide maintains high resistance to enzymatic cleavage, resulting in prolonged biological activity across all three target receptors. These structural features collectively contribute to the favorable pharmacokinetic profile of Retatrutide, characterized by high bioavailability, sustained plasma concentrations, and predictable accumulation after repeated dosing. The physical properties of Retatrutide include good solubility in DMSO and alkaline solutions, with a pH of approximately 5.0 to 6.5 when reconstituted at 1 milligram per milliliter in water. The lyophilized powder is white to off-white in appearance and forms a clear, colorless solution upon proper reconstitution with sterile water for research use, 0.9% saline, or sterile bacteriostatic water. Stability studies have shown that the lyophilized powder remains stable for at least 24 months at -20°C, for at least 12 months at 4°C, and for at least seven days at 25°C when protected from light. After reconstitution, the solution should be stored at 4°C and used within 24 to 48 hours, or aliquoted and frozen at -20°C for up to one month, with repeated freeze-thaw cycles strictly avoided.

The mechanism of action of Retatrutide is fundamentally different from all other incretin-based peptides because it simultaneously activates three distinct hormone receptors: GIP, GLP-1, and glucagon. This triple receptor agonism produces complementary and synergistic effects on glucose metabolism, body weight regulation, and energy expenditure that cannot be achieved with single or dual agonists. When Retatrutide binds to GIP receptors on pancreatic beta cells, it activates intracellular cyclic adenosine monophosphate (cAMP) signaling pathways, leading to glucose-dependent insulin secretion. The term "glucose-dependent" means that insulin release is strongly stimulated only when blood glucose levels are elevated, and the effect is significantly reduced when blood glucose is normal, a characteristic that greatly lowers the risk of hypoglycemia. In addition to promoting insulin secretion, GIP receptor activation also supports beta cell survival and function by promoting beta cell proliferation and reducing apoptosis, which contributes to long-term pancreatic health. GIP also influences lipid metabolism in adipose tissue, promoting healthy fat distribution, and may positively influence bone formation through receptors present on osteoblasts. Meanwhile, activation of the GLP-1 receptor produces its own set of beneficial effects. GLP-1 potentiates insulin release from pancreatic beta cells in a glucose-dependent manner, inhibits glucagon secretion from pancreatic alpha cells to reduce hepatic glucose production, delays gastric emptying to reduce postprandial glucose spikes, and acts on GLP-1 receptors in the hypothalamus to increase satiety and reduce food intake. What makes Retatrutide truly unique is the addition of glucagon receptor agonism. Glucagon is a hormone that normally works in opposition to insulin, promoting glucose production and lipolysis. However, when combined with GIP and GLP-1 activation, glucagon receptor agonism produces several beneficial metabolic effects. Glucagon increases energy expenditure by promoting thermogenesis in brown adipose tissue, enhances lipolysis and fatty acid oxidation, reduces food intake through central mechanisms, and improves lipid profile by reducing triglycerides and increasing HDL cholesterol. The combination of GIP, GLP-1, and glucagon receptor activation produces effects that are greater than the sum of their individual contributions, resulting in superior glycemic control, more substantial and sustained body weight reduction, increased energy expenditure, favorable changes in lipid profile, and a reduction in gastrointestinal side effects compared to what might be expected from single or dual agonism alone.

Retatrutide is widely used in various areas of metabolic research, and its triple agonism mechanism opens up new possibilities that were previously unavailable to researchers. In type 2 diabetes research, Retatrutide serves as a valuable tool for studying the complementary roles of GIP, GLP-1, and glucagon in glucose homeostasis, investigating glucose-dependent insulin secretion mechanisms, exploring beta cell preservation and regeneration, evaluating combination therapies for diabetes management, and advancing personalized medicine approaches based on incretin and glucagon response profiles. In obesity and weight management research, the potent weight-reducing effects of Retatrutide, which are significantly greater than those observed with dual or single agonists, make it an excellent research tool for investigating central nervous system pathways that regulate appetite, studying energy expenditure and metabolic rate through glucagon-mediated thermogenesis, researching body composition changes during weight loss, and evaluating long-term weight maintenance strategies. In metabolic syndrome research, Retatrutide affects multiple components of metabolic syndrome, making it suitable for studies on dyslipidemia and lipid metabolism, hypertension and blood pressure regulation, insulin resistance and metabolic dysfunction, and inflammatory markers associated with metabolic disease. In cardiovascular research, preclinical studies suggest that GIP, GLP-1, and glucagon receptor activation may have direct and indirect cardiovascular benefits, including improved endothelial function, reduced atherosclerosis progression, favorable cardiac remodeling, and reduced inflammatory pathways. The addition of glucagon agonism may provide additional cardiovascular benefits through increased energy expenditure and improved lipid profile. In non-alcoholic fatty liver disease research, Retatrutide has shown significant promise in reducing hepatic steatosis, inflammation, and fibrosis through multiple mechanisms, including direct effects on hepatic lipid metabolism, increased fatty acid oxidation, and reduced de novo lipogenesis. This makes Retatrutide particularly valuable for studies on hepatic lipid metabolism, fibrosis progression and regression, the gut-liver axis in metabolic disease, and combination therapies for NAFLD and NASH. In energy metabolism research, Retatrutide provides a unique tool for studying the role of glucagon in energy homeostasis, investigating the mechanisms of adaptive thermogenesis, exploring the interplay between different metabolic hormones, and developing new therapeutic strategies for metabolic diseases.

Proper reconstitution of Retatrutide is essential for maintaining the stability and activity of the peptide. The recommended reconstitution protocol begins with briefly centrifuging the sealed vial to ensure all lyophilized powder collects at the bottom. The researcher then chooses an appropriate diluent, such as sterile water for research use, 0.9% sodium chloride solution, or sterile bacteriostatic water containing 0.9% benzyl alcohol. Using a sterile syringe, the diluent is added to the vial, directing the stream against the glass wall to avoid creating excessive foam. The vial is then gently swirled until the solution is clear and free of visible particles, with vigorous shaking or vortexing avoided to prevent peptide aggregation or degradation. The reconstituted solution should be clear, colorless, and free of particulates. For a 5 milligram vial, adding 0.5 milliliters of diluent yields a concentration of 10 milligrams per milliliter, while adding 1.0 milliliter yields 5 milligrams per milliliter. For a 10 milligram vial, adding 1.0 milliliter yields 10 milligrams per milliliter, and adding 2.0 milliliters yields 5 milligrams per milliliter. For a 20 milligram vial, adding 2.0 milliliters yields 10 milligrams per milliliter, and adding 4.0 milliliters yields 5 milligrams per milliliter. After reconstitution, the solution should be stored at 4°C and used within 24 to 48 hours, or aliquoted into single-use vials and frozen at -20°C for up to one month. Repeated freeze-thaw cycles must be avoided, as they can degrade the peptide and reduce its biological activity.

Boyuan applies rigorous quality control specifications to every batch of Retatrutide. Each product is accompanied by a Certificate of Analysis containing detailed test results for multiple parameters. Appearance is verified as white to off-white lyophilized powder by visual inspection. Identity is confirmed by HPLC retention time matching a reference standard. Purity is measured by RP-HPLC and must be at least 99.0 percent. Single impurities must not exceed 0.5 percent, and total impurities must not exceed 1.0 percent. Peptide content is determined by amino acid analysis and must be between 90.0 and 110.0 percent of the labeled amount. Water content is measured by Karl Fischer titration and must not exceed 5.0 percent. Acetate content is measured by ion chromatography and must not exceed 12.0 percent. Bacterial endotoxins are measured by the LAL test and must not exceed 1.0 EU per milligram. These rigorous quality control measures ensure that researchers receive a product that is consistent, pure, and reliable for their experimental needs.

Boyuan has compiled answers to frequently asked questions to assist researchers working with Retatrutide. The first question is whether the product is sterile. Boyuan's Retatrutide lyophilized powder is filled under aseptic conditions in a GMP-compliant facility. If sterile conditions are required for research, filter sterilization using a 0.22-micron membrane filter after reconstitution is recommended. The second question asks about the difference between Retatrutide, Tirzepatide, and Semaglutide. Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors, while Tirzepatide is a dual agonist targeting GIP and GLP-1 receptors, and Semaglutide is a selective GLP-1 receptor agonist. The addition of glucagon agonism in Retatrutide provides unique effects on energy expenditure and thermogenesis that are not seen with the other peptides. The third question concerns the solubility of Retatrutide. Retatrutide is soluble in DMSO and alkaline solutions. For aqueous solutions, it is recommended to first dissolve the peptide in a small volume of sterile water or saline. The fourth question asks whether Retatrutide can be mixed with other peptides. Boyuan does not recommend mixing Retatrutide with other peptides in the same vial for storage, as different peptides have varying optimal pH values, stability profiles, and compatibility characteristics, and mixing may lead to precipitation, aggregation, or degradation. The fifth question asks about the recommended storage temperature. Unopened lyophilized Retatrutide should be stored at -20°C in a dry, light-protected environment, avoiding repeated freeze-thaw cycles. The sixth question asks whether Boyuan provides bulk or customized packaging. Yes, Boyuan can provide custom packaging solutions for bulk orders, including different vial sizes, custom labels, and specialized cold chain shipping configurations. The seventh question asks about the minimum order quantity. The minimum order quantity for most RT series products is one box, with bulk discounts available for larger quantities. The eighth question asks how long shipping takes. Shipping times vary by destination and shipping method, with standard delivery to most international destinations taking three to seven business days for in-stock items, and express shipping options also available. The ninth question asks about the stability of Retatrutide compared to other peptides. Due to its fatty acid modification and DPP-4 resistance, Retatrutide has excellent stability comparable to or better than other incretin-based peptides, with a half-life of approximately six days in vivo and excellent stability in lyophilized form. The tenth question asks whether Retatrutide can be used in animal studies. Yes, Retatrutide is widely used in animal studies, particularly in mouse and rat models of obesity, diabetes, and metabolic syndrome. The recommended subcutaneous dose range for mice is 10 to 100 micrograms per kilogram of body weight, administered once daily, every other day, or once weekly depending on the study design.

For international customers, Boyuan has extensive experience in exporting Retatrutide products. Products can be shipped to North America, Europe, Southeast Asia, the Middle East, Australia, and other regions, supporting air and sea freight, and providing customs clearance assistance documents based on destination requirements. Boyuan recommends that customers understand the import regulations for peptide research products in their country or region before purchasing to ensure smooth customs clearance. In terms of pricing, Boyuan maintains a competitive pricing strategy, striving to provide customers with the best value for money without compromising product quality. Bulk purchases can enjoy further discounts, and long-term cooperation customers can obtain more flexible payment methods and priority shipping rights. Boyuan also offers other specifications of Retatrutide beyond RT10, including RT5 (5 milligrams per vial), RT15 (15 milligrams per vial), RT20 (20 milligrams per vial), RT30 (30 milligrams per vial), RT40 (40 milligrams per vial), and RT60 (60 milligrams per vial), each box containing 10 vials, allowing researchers to choose the appropriate specification based on their experimental needs. For researchers who require other quantities or custom packaging, Boyuan's sales team is available to discuss specific requirements.